Seroatlas · Human Serome Atlas

ADAT2

tRNA-specific adenosine deaminase 2

Also known as: ADAT2_HUMAN, DEADC1, dJ20N2.1, TAD2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q7Z6V5
Gene: ADAT2
Ensembl: ENSG00000189007
Chromosome: 6
Canonical length: 191 aa
Protein class: Enzymes, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Golgi apparatus,Cytosol

OverviewNCBI Gene

Predicted to enable tRNA-specific adenosine-34 deaminase activity. Predicted to be involved in tRNA wobble adenosine to inosine editing. Predicted to be located in nucleoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

191 residues, UniProt reviewed canonical sequence.

>Q7Z6V5|ADAT2
     1  MEAKAAPKPA ASGACSVSAE ETEKWMEEAM HMAKEALENT EVPVGCLMVY NNEVVGKGRN
    61  EVNQTKNATR HAEMVAIDQV LDWCRQSGKS PSEVFEHTVL YVTVEPCIMC AAALRLMKIP
   121  LVVYGCQNER FGGCGSVLNI ASADLPNTGR PFQCIPGYRA EEAVEMLKTF YKQENPNAPK
   181  SKVRKKECQK S

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ADAT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 5.2 nTPM

Expression across tissuesHPA

Tissue

skin: 5.2 nTPM
bone marrow: 5.1 nTPM
liver: 4.9 nTPM
pancreas: 4.7 nTPM
spleen: 4.4 nTPM
esophagus: 4.3 nTPM

Single-cell type

megakaryocyte-erythroid progenitors: 59 nCPM
choroid plexus epithelial cells: 38 nCPM
erythrocyte progenitors: 37 nCPM
pituitary stem cells: 34 nCPM
alveolar cells type 1: 34 nCPM
microglia: 30 nCPM

Immune cell

T-reg: 1.3 nTPM
naive CD8 T-cell: 1 nTPM
MAIT T-cell: 0.8 nTPM
naive CD4 T-cell: 0.7 nTPM
gdT-cell: 0.6 nTPM
myeloid DC: 0.6 nTPM

Brain region

cerebellum: 4.8 nTPM
choroid plexus: 4.8 nTPM
hypothalamus: 4.2 nTPM
cerebral cortex: 4.1 nTPM
white matter: 4 nTPM
amygdala: 3.9 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.57
gnomAD pLI: 0
gnomAD missense Z: 0.88
DepMap mean gene effect: -0.19
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

tRNA wobble adenosine to inosine editing

Molecular functions

zinc ion binding
tRNA-specific adenosine-34 deaminase activity

Cellular components

nucleoplasm

Protein domainsUniProt · Pfam · InterPro

Cytidine and deoxycytidylate deaminase domain
APOBEC/CMP deaminase, zinc-binding
Cytidine deaminase-like
Cytidine and deoxycytidylate deaminase zinc-binding region
tRNA-specific adenosine deaminase

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ADAT2 as an antibody target. Whether an autoantibody or antibody against ADAT2 could matter depends on whether native ADAT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ADAT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ADAT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...